 |
 |

UV-A1 Phototherapy for Sclerotic Skin DiseasesImplications for Optimizing Patient Selection and Management
Alexander Kreuter, MD;
Thilo Gambichler, MD
Arch Dermatol. 2008;144(7):912-916.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Phototherapy is among our most powerful weapons for fighting against chronic inflammatory skin diseases. Since the middle of the past century, numerous controlled studies of broadband UV-B, narrowband UV-B, and psoralen plus UV-A have demonstrated that phototherapy is highly effective in treating cutaneous diseases, such as psoriasis and atopic dermatitis. In 1981, the development of a new lamp that emits radiation predominantly between 340 and 400 nm was described, introducing the era of UV-A1 phototherapy.1 Three different dosage regimens of UV-A1 are distinguished: high-, medium-, and low-dose UV-A1, emitting 90 to 130, 30 to 89, and less than 30 J/cm2, respectively. In contrast to UV-B, which penetrates into the papillary dermis only, longer wavelengths in the UV-A region can reach the subcutis as well. In 1992, UV-A1 was first introduced as a highly potent treatment option for acute atopic dermatitis.2 Three years later, . . . [Full Text of this Article]INDICATIONS FOR TREATMENT AND UV-A1 DOSAGE
MECHANISM OF ACTION AND TREATMENT SCHEDULE FOR UV-A1
EVALUATION OF TREATMENT RESPONSE
LIMITATIONS OF UV-A1 IN SCLEROTIC SKIN DISEASES
AUTHOR INFORMATION
RELATED ARTICLE
Effect of Increased Pigmentation on the Antifibrotic Response of Human Skin to UV-A1 Phototherapy
Frank Wang, Luis A. Garza, Soyun Cho, Reza Kafi, Craig Hammerberg, Taihao Quan, Ted Hamilton, Maureen Mayes, Voravit Ratanatharathorn, John J. Voorhees, Gary J. Fisher, and Sewon Kang
Arch Dermatol. 2008;144(7):851-858.
ABSTRACT
| FULL TEXT
|